Neostem, Inc. (NBS)
-NYSE MKT | Prev Close: | 0.59 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 3.25 |
|---|
| Beta: | 1.42 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 0.35 - 0.84 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 1,124,770 |
|---|
| Market Cap: | 100.46M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.36 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- NEOSTEM, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- 4 Healthcare Stock Stories For Thursday Investing Wellnessat Wall St. Cheat Sheet(Thu, May 16)
- NeoStem announces geographic expansion of IP coverage of AMR-001theflyonthewall.com(Thu, May 16)
- NeoStem Announces Geographic Expansion of Intellectual Property Coverage of Cardiovascular Asset AMR-001GlobeNewswire(Thu, May 16)
- 3 Biotech Stocks With Potentialat Seeking Alpha(Tue, May 14)
- NeoStem to Present at Multiple Conferences in MayGlobeNewswire(Tue, May 14)
- NeoStem's Subsidiary, Progenitor Cell Therapy, to Provide Autologous and Allogeneic Cellular Therapy Services to MedStar Georgetown University HospitalGlobeNewswire(Mon, May 13)
- 5 Stocks To Watch For Gains Next Weekat Seeking Alpha(Sat, May 11)
- NeoStem Clarification: No New Securities Being IssuedGlobeNewswire(Thu, May 9)
- NeoStem CEO's Letter to ShareholdersGlobeNewswire(Thu, May 9)
- NEOSTEM, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Interviewing Dr. Losordo: The Promising Development Of CD34 Cellsat Seeking Alpha(Wed, May 8)
- NeoStem Announces Closing of Public Offering of Common StockGlobeNewswire(Fri, May 3)
- Stem Cells: Invest At Your Own Perilat Seeking Alpha(Wed, May 1)
- NEOSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Wed, May 1)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 7.68 |
|---|
| Ex-Dividend Date: | 04-Apr-11 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.17 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.04 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | -0.06 |
|---|
Business Summary
NeoStem, Inc. engages in the development of proprietary cell therapy products. It is involved in the manufacture of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution...
View More 
0.80%